Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 13/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ACACA | Q13085 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18592240 | 0.88 | HPGD (0.43) | ACACBHPGDLMNAACACAALDH1A1 | |
| SCHEMBL18611816 | 0.88 | ACACB (0.45) | ACACBHPGDLMNAACACAALDH1A1 | |
| SCHEMBL21341632 | 0.87 | ACACB (0.46) | ACACBHPGDLMNAACACA | |
| SCHEMBL20231660 | 0.87 | ACACB (0.44) | ACACBHPGDLMNAACACAALDH1A1 | |
| SCHEMBL24856112 | 0.87 | ACACB (0.44) | ACACBHPGDLMNAACACAALDH1A1 | |
| SCHEMBL20233645 | 0.81 | ALDH1A1 (0.44) | LMNAALDH1A1GAAKMT2A | |
| SCHEMBL20322561 | 0.80 | ALDH1A1 (0.43) | LMNAALDH1A1GAAKMT2A | |
| SCHEMBL20233831 | 0.80 | ALDH1A1 (0.43) | LMNAALDH1A1GAAKMT2A | |
| SCHEMBL18612212 | 0.79 | APP (0.50) | ALDH1A1GAA | |
| SCHEMBL21906681 | 0.79 | ACACB (0.40) | ACACBHPGDLMNAACACAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | UNIV YALE (US) | 2020-04-23 | — | — | US | disclosed |
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179183-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | ACACB 1533/4885HPGD 4053/4885LMNA 1887/4885 |
| US-20200121684-A1 | MODULATORS OF BTK PROTEOLYSIS AND METHODS OF USE | BTK, CBL, CRBN | ACACB 1780/4885HPGD 4471/4885LMNA 2479/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | ACACB 1533/4885HPGD 4053/4885LMNA 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.